Excellergy Inc.

Excellergy Inc. is a US-based biotech company focused on developing innovative therapeutics, specifically Effector Cell Response Inhibitors, targeting severe allergic diseases to improve patient outcomes. Founded in 2022 in Palo Alto, US, Excellergy Inc. specializes in allergy therapeutics, notably Effector Cell Response Inhibitors.

The company has engaged in two distinct deals, with its latest Series A funding round in October 2025 amounting to USD 70 mn led by Samsara BioCapital, and also involved Decheng Capital and Red Tree Venture Capital. This round marks the total amount raised by the company as USD 70 mn. Excellergy specializes in pioneering Effector Cell Response Inhibitors (ECRIs) for treating severe allergic diseases. Their products effectively target Immunoglobulin E (IgE) to control allergic responses, focusing on conditions such as allergic asthma and atopic dermatitis.

The product line primarily serves healthcare providers and clinics in North America and Europe. Excellergy operates on a B2B revenue model, partnering with healthcare providers for the distribution of their ECRIs. Their flagship product, Exl-111, is central to their sales strategy, which includes negotiated contracts with hospitals emphasizing volume-based pricing and patient outcome reimbursements. The company's financial strategy is supported by their Series A funding, enhancing their market presence in the allergy therapeutics sector.

In March 2026, Novartis International AG agreed to acquire Excellergy Inc. from Red Tree Venture Capital, Decheng Capital, and Samsara BioCapital for an upfront payment of USD 2 billion and milestone payments.